Review Article

Review of the History and Current Status of Cell-Transplant Approaches for the Management of Neuropathic Pain

Table 1

Primary tissue used for cell therapy.

Source Pain model Results

Primary cells/tissue:
Adrenal-rat [49, 57, 58, 219, 245249]
Bovine [35, 59, 247, 250254]
Encapsulated bovine [247, 255258]
bovine scaffolds [259]
Porcine [253, 254, 260262]
Encapsulated porcine [262]
Human [62, 67, 71, 263, 264]
Human encapsulated [67]
Acute [247]
Midbrain [38]
Formalin [54, 58, 247, 249, 253, 260, 261]
Nerve injury [46, 57, 67, 256, 262]
Dorsal rhizotomy [246]
Excitotoxic SCI [219, 255, 265]
Hemisection SCI [245]
Human Cancer [64, 71, 266, 267]
Arthritis [56, 65, 268]
(i) Reduced “excessive grooming” behaviors [219]
(ii) Reduction or stabilization in complementary opioid intake in human cancer [71]
(iii) Reductions in both fore- and hindlimb mechanical and thermal allodynia [245]
(iv) Failed antinociception after intraventricular transplant [256]
(v) Reduces edema, anterograde axoplasmic transport [249]
(vi) Restores spinal GABA-ir decreased spinal c-Fos [58, 253]
(vii) Failed antinociception [247, 247, 269271]
(viii) Reduced cold or TA/TH behaviors [67, 219, 262]
(ix) Reduced tonic pain behaviors [261]
(x) Delayed, reduced self-directed pain behaviors [246]
(xi) Antinociceptive effects on A-delta and C-fiber-mediated responses [59]
(xiii) Long-term proenk and tyrosine hydroxlylase in grafts [248]
(xiv) Reduce forelimb/hindlimb allodynia [245]